Myriad Genetics (MYGN) Tops Q4 EPS by 5c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Myriad Genetics (MYGN) PT Raised to $52 at Stephens
August 22, 2018 6:12 AM EDTStephens analyst Drew Jones raised the price target on Myriad Genetics (NASDAQ: MYGN) to $52.00 (from $45.00) while maintaining a Overweight rating.
... MoreMyriad Genetics (MYGN) PT Raised to $38 at Piper Jaffray
August 22, 2018 6:01 AM EDTPiper Jaffray analyst William Quirk raised the price target on Myriad Genetics (NASDAQ: MYGN) to $38.00 (from $32.00) while maintaining a Neutral rating.
... More